Northern Trust’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-1,748,286
| Closed | -$10.5M | – | 4324 |
|
|
2019
Q4 | $10.5M | Buy |
1,748,286
+36,694
| +2% | +$212K | ﹤0.01% | 2148 |
|
|
2019
Q3 | $6.16M | Buy |
1,711,592
+103,081
| +6% | +$397K | ﹤0.01% | 2430 |
|
|
2019
Q2 | $4.31M | Sell |
1,608,511
-16,362
| -1% | -$48.3K | ﹤0.01% | 2642 |
|
|
2019
Q1 | $4.81M | Buy |
1,624,873
+9,781
| +0.6% | +$24K | ﹤0.01% | 2587 |
|
|
2018
Q4 | $2.57M | Sell |
1,615,092
-13,330
| -0.8% | -$37.7K | ﹤0.01% | 2911 |
|
|
2018
Q3 | $5.99M | Buy |
1,628,422
+23,600
| +1% | +$70.3K | ﹤0.01% | 2589 |
|
|
2018
Q2 | $4.54M | Buy |
1,604,822
+30,669
| +2% | +$104K | ﹤0.01% | 2725 |
|
|
2018
Q1 | $5.84M | Buy |
1,574,153
+131,219
| +9% | +$429K | ﹤0.01% | 2494 |
|
|
2017
Q4 | $4.16M | Buy |
1,442,934
+15,654
| +1% | +$56.9K | ﹤0.01% | 2716 |
|
|
2017
Q3 | $6.41M | Buy |
1,427,280
+459
| +0% | +$2.04K | ﹤0.01% | 2469 |
|
|
2017
Q2 | $6.55M | Sell |
1,426,821
-57,697
| -4% | -$232K | ﹤0.01% | 2448 |
|
|
2017
Q1 | $6.25M | Buy |
1,484,518
+40,974
| +3% | +$170K | ﹤0.01% | 2420 |
|
|
2016
Q4 | $5.96M | Buy |
1,443,544
+8,292
| +0.6% | +$44.1K | ﹤0.01% | 2438 |
|
|
2016
Q3 | $11.6M | Sell |
1,435,252
-24,708
| -2% | -$210K | ﹤0.01% | 1965 |
|
|
2016
Q2 | $11.4M | Buy |
1,459,960
+78,493
| +6% | +$673K | ﹤0.01% | 1938 |
|
|
2016
Q1 | $10.7M | Buy |
1,381,467
+15,904
| +1% | +$116K | ﹤0.01% | 1932 |
|
|
2015
Q4 | $14.7M | Sell |
1,365,563
-2,259
| -0.2% | -$20.5K | ﹤0.01% | 1728 |
|
|
2015
Q3 | $9.45M | Buy |
1,367,822
+133,815
| +11% | +$1.09M | ﹤0.01% | 2029 |
|
|
2015
Q2 | $10.9M | Sell |
1,234,007
-42,372
| -3% | -$401K | ﹤0.01% | 2012 |
|
|
2015
Q1 | $12.6M | Buy |
1,276,379
+217,529
| +21% | +$2.72M | ﹤0.01% | 1928 |
|
|
2014
Q4 | $13M | Sell |
1,058,850
-21,410
| -2% | -$261K | ﹤0.01% | 1879 |
|
|
2014
Q3 | $10.8M | Buy |
1,080,260
+2,448
| +0.2% | +$22.7K | ﹤0.01% | 1982 |
|
|
2014
Q2 | $8.16M | Sell |
1,077,812
-173,340
| -14% | -$692K | ﹤0.01% | 2182 |
|
|
2014
Q1 | $4.12M | Sell |
1,251,152
-119,564
| -9% | -$418K | ﹤0.01% | 2685 |
|
|
2013
Q4 | $4.55M | Sell |
1,370,716
-5,158
| -0.4% | -$15K | ﹤0.01% | 2638 |
|
|
2013
Q3 | $4.16M | Buy |
1,375,874
+195,479
| +17% | +$1.34M | ﹤0.01% | 2639 |
|
|
2013
Q2 | $9.66M | Buy |
+1,180,395
| New | +$9.01M | ﹤0.01% | 1947 |
|
Northern Trust's ACHN Position: Q1 2020 in Review
Northern Trust sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 1,748,286 shares — an estimated $10.5M sold.
Northern Trust first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $14.7M in Q4 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Northern Trust reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Northern Trust sold 1,748,286 Achillion Pharmaceuticals shares in Q1 2020, an estimated $10.5M.
- Northern Trust first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Northern Trust's Achillion Pharmaceuticals position peaked at $14.7M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Northern Trust's 13F filing for Q1 2020, filed 14 May 2020.